Spruce Biosciences: nasa tamang landas ang pagsusumite ng BLA ng TA-ERT para sa Q4 2026

Kasunod ng mga positibong Type B meetings, kinumpirma ng FDA na ang integrated study data at natural history data ay maaaring magsilbing sapat at well-controlled study na sumusuporta sa accelerated approval sa pamamagitan ng CSF heparan sulfate non-reducing end bilang isang reasonably likely surrogate endpoint. Muling binanggit ng kumpanya ang kanilang plano na isumite ang BLA para sa TA-ERT sa ika-apat na quarter ng 2026.

Mahahalagang fact

Na-file: Mar 20, 2026, 09:04 PM
Kaganapan: Naisumite ang aplikasyon
Direksyon: Positibo
Kumpanya: SPRBSpruce Biosciences
Asset: tralesinidase alfa
Pinagmulan: SEC 8-K
Kumpiyansa: May source

Sipi mula sa source

EX-99.1 2 sprb-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates Following Positive Type B Meetings with the FDA, BLA Submission for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) on Track for the Fourth Quarter of 2026 Appoints Dale Hooks as Chief Commercial Officer, Strengthening the Company’s Commercial Capabilities in Preparation for a Potential Launch of TA-ERT Secured up to $50 Million in Growth Capital from Avenue Capital Group South San Francisco, Calif. – March 9, 2026 – Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today

SEC 8-K